- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01719510
Interest of the Detection of Hyper-virulent Clone ST17 of Group B Strep (GBS) for the Prevention of Neonatal GBS Meningitis (Col-Strepto B)
Study of the Digestive Colonization of the Newborn Children by the Streptococcus of the Group B
The main objective of this study : Demonstrate that GBS (group B streptococci) "ST-17" colonize and persist to 60 days twice in the digestive tract of newborns that strains of GBS non-ST-17.
Secondary objectives:Determine:
- The frequency of colonization with GBS ST-17 and GBS non-ST-17 of at risk pregnant women.
- The frequency of colonization of neonates by GBS ST-17 at birth.
- The preferential site of colonization in the mother (rectum, vagina, breast milk).
- The kinetics of colonization after birth in the newborn.
- The sensitivity and specificity of different GBS detection methods (conventional phenotypic versus molecular) in the different types of samples from the mother and the newborn.
Study Overview
Status
Intervention / Treatment
Detailed Description
Women tested positive for GBS during systematic vaginal screening at 35-37 weeks, will be proposed to participate to the study and will be included after reading the information letter and signature the consent form.
INCLUSION (D0 at time of delivery)
In the labor ward, two women's groups 1 and 2:
Group 1 = Women tested positive for GBS pre-selected and included in the protocol (see pre-inclusion) Group 2 = Women without antenatal vaginal screening and at risk of neonatal infection.
For both groups, at time of delivery:
At the beginning of the labour performed vaginal swabs (PV0):
- one swab for GBS detection by real-time PCR using the Cepheid technique conducted in the labor ward by the midwife.
- the second swab for GBS detection by conventional bacteriological techniques and sent to the bacteriology laboratory.
For all women included (Group 1 and Group 2 women with a positive GBS vaginal sample) will be achieved in the delivery room:
- To the mother: A blood sample of 5 ml at the time of the implementation of the IV line.
- A sampling of umbilical cord blood. Newborns of mothers included (group 1 and 2) will have a search for GBS (standard culture) in the stools and the pharynx prior to return home. Samples will be sent to the bacteriology laboratory and analyzed by classical bacteriological method (culture) and / or real-time PCR.
For mothers, the collection of 3-5 ml of milk when breastfeeding.
Monitoring schedule:
Day 21 and day 60 post delivery:
the following samples for search of GBS for will be performed to gather the primary endpoint:
For the mother:
- Vaginal sample.
- Collection of 3-5 ml of breast milk when breastfeeding
For the newborn:
- Sample collection of feces
- Swab of buccal cavity
Processing bacteriological samples:
All samples will be subjected to bacteriological analysis and DNA extraction for detection of GBS. GBS isolated will be identified and stored at - 80 ° C in a declared biological collection. DNA extracts will also stored at -20 ° C in a declared biological collection. All samples for microbiological analysis will be stored at - 80 ° C.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Colombes, France, 92 700
- Louis Mourier Hospital
-
Paris, France, 75014
- Cochin Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient having a positive vaginal swab for GBS at the end of pregnancy (PCR +).
- Patient aged over 18 years
- Patient who received information and agreeing to sign informed consent
- Patient affiliated or beneficiary of an insurance
Exclusion Criteria:
- Patient does not speak and does not understand French
Study Plan
How is the study designed?
Design Details
- Primary Purpose: SCREENING
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Positive Group B Streptococcus vaginal sample
At time of delivery we will performed vaginal swabs in two groups: women tested positive for GBS at 35-37 weeks and women with risk of neonatal infection. For all women included will be achieved in the delivery room: a blood sample to the mother and a sampling of umbilical cord blood. Newborns will have a search for GBS (standard culture) in the stools and the pharynx. For mothers, the collection of milk when breastfeeding. |
At time of delivery we will performed vaginal swabs in two groups: women tested positive for GBS at 35-37 weeks and women with risk of neonatal infection. For both groups:
For all women included will be achieved in the delivery room:
Newborns of mothers included (group 1 and 2) will have a search for GBS (standard culture) in the stools and the pharynx prior to return home. For mothers, the collection of 3-5 ml of milk when breastfeeding. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Detection of the hyper-virulent ST17 clone of Group B Strep
Time Frame: at 60 days post delivery
|
Detection of the hyper-virulent ST17 clone of Group B Strep (GBS) in the prevention of neonatal GBS meningitis.
The main objective is to demonstrate that the hypervirulent ST17 GBS clone colonizing the mother and postpartum acquired colonizes and persists at 60 days post delivery in the gut of new born significantly more than non-ST17 GBS strains.
|
at 60 days post delivery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Digestive colonization
Time Frame: at day 21
|
Digestive colonization of ST17 clone of Group B Strep in the newborns
|
at day 21
|
Milk colonization
Time Frame: at day 21 and day 60
|
Colonization of milk by ST17 clone of Group B Strep
|
at day 21 and day 60
|
Vaginal colonization
Time Frame: at day 21 and day 60
|
Vaginal colonization by ST17 clone of Group B Strep
|
at day 21 and day 60
|
Late neonatal infections
Time Frame: between 3 weeks and 60 days
|
Late neonatal infections will be observed between 3 weeks and 60 days
|
between 3 weeks and 60 days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Claire POYART, MD, PhD, Cochin Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- P111008
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neonatal Infections Colonize With Group B Streptococci
-
Eunice Kennedy Shriver National Institute of Child...CompletedGroup B Streptococci | Respiratory Distress in NewbornUnited States
-
St George's, University of LondonMRC/UVRI and LSHTM Uganda Research Unit; MU-JHU CARECompletedGroup B Streptococcus Carrier in Childbirth | Group B Streptococcal Infection, Late-Onset | Group B Streptococcal Infection, Early-Onset | Group B Streptococcus Neonatal Sepsis | Group B Strep InfectionUganda
-
St George's, University of LondonMRC/UVRI and LSHTM Uganda Research Unit; MU-JHU CAREUnknownGroup B Streptococcus Carrier in Childbirth | Group B Streptococcal Infection, Late-Onset | Group B Streptococcal Infection, Early-Onset | Group B Streptococcus Neonatal Sepsis | Group B Strep InfectionUganda
-
St George's, University of LondonAssistance Publique - Hôpitaux de Paris; MRC/UVRI and LSHTM Uganda Research... and other collaboratorsRecruitingGroup B Streptococcus Carrier in Childbirth | Group B Streptococcal Infection, Late-Onset | Group B Streptococcal Infection, Early-Onset | Group B Streptococcus Neonatal Sepsis | Group B Strep InfectionFrance, Italy, Malawi, Netherlands, Uganda, United Kingdom
-
University of MichiganWithdrawnGroup B Streptococcus Neonatal SepsisUnited States
-
Assuta Hospital SystemsCompletedStreptococcal Infection Group B as Cause of Diseases Classified Elsewhere (Diagnosis)
-
HCA International LimitedUnknownGroup B StreptococcusUnited Kingdom
-
St George's, University of LondonUnknownGroup B StreptococcusUnited Kingdom
-
Minervax ApSCompletedInfection by Streptococcus Group BUnited Kingdom
-
University of New MexicoMarquette UniversityActive, not recruitingGroup B Strep InfectionUnited States
Clinical Trials on Samples
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Centre Georges Francois LeclercCompleted
-
Centre Hospitalier Universitaire de NīmesCompletedHenoch Schönlein PurpuraFrance
-
Centre Hospitalier Universitaire DijonCompletedPrimary Immune Thrombocytopenia (ITP)France
-
Institut BergoniéUnknown
-
Gustave Roussy, Cancer Campus, Grand ParisUnknownPaediatric MalignanciesFrance
-
Assistance Publique - Hôpitaux de ParisActive, not recruiting
-
University Hospital, BordeauxRecruitingSystemic Sclerosis | SclerodermaFrance
-
Centre Hospitalier Universitaire, AmiensCompleted
-
Innovaderm Research Inc.RecruitingPlaque Psoriasis | Atopic Dermatitis | Hidradenitis Suppurativa | Palmoplantar Pustulosis | Acne | Chronic Hand EczemaCanada